Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China

European Journal of Nuclear Medicine

Volumn 26, Issue 1, 1999, Pages 2-7

  Tian, Jia He ^a   Zhang, Jin Ming ^a   Hou, Qing Tian ^b   Oyang, Qiao Hong ^c   Wang, Jian Min ^d   Luan, Zhao Sheng ^e   Chuan, Ling ^f   He, Yi Jie ^a  

^a Great Wall Hospital   (China)

^b Hangong General Hospital   (China)

^c Yuyuantan Hospital   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

^e PLA   (China)

^f NAVY GENERAL HOSPITAL   (China)

Author keywords

Palliative treatment; Radiopharmaceutical therapy; Samarium 153 ethylene diamine tetramethylene phosphonate; Skeletal metastases

Indexed keywords

ANALGESIC AGENT; LEXIDRONAM SAMARIUM SM 153;

ADULT; AGED; ARTICLE; BLOOD DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER PAIN; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; ESOPHAGUS CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PALLIATIVE THERAPY; SCORING SYSTEM; SINGLE BLIND PROCEDURE; THROMBOCYTE COUNT;

ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; CHINA; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PALLIATIVE CARE; RADIOISOTOPES; RADIOTHERAPY DOSAGE; SAMARIUM;

EID: 0033061339     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050351     Document Type: Article

References (10)

1. 1. Campa JA III, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med 1992; 22: 3-10.
2. 153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med 1992; 22: 41-45.
3. 3. Clarke SEM. Radionuclide therapy in oncology. Can Treat Rev 1994; 20: 51-72.
4. 4. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDT-MP in bone metastases of hormone refractory prostate carcianoma. A phase I/II trial. J Nucl Med 1993; 34: 1839-1844.
5. 153Sm-EDTMP in the treatment of patients with painful bone metastases. Eur J cancer 1997; 33: 1583-1591.
6. 6. Serafini AN, Houston SJ, Resch I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: a double-blind placebo controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
7. 7. McNeil BJ. Value of bone scanning in neoplastic diseases. Semin Nucl Med 1984; 14: 277-286.
8. 8.Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastases [editorial]. J Nucl Med 1996; 37: 249-252.
9. 9. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34: 1031-1036.
10. 10. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153-ethylenediamine-tetramethylene phosphate. Eur J Nucl Med 1991; 27: 1084-1086.